Home > News >
GENOMA ESPAÑA THROUGH INNOCASH PROGRAM PROVIDES €450,000 TO HISTOCELL.
Histocell, the Clínic Hospital of Barcelona and CSIC have completed a licensing agreement under which the Basque biotechnology commits a minimum of €3 million and its ability to industrialize cell drugs to move over the next three years in the development of drugs for the treatment of idiopathic pulmonary fibrosis.
Genoma España, through Innocash program, will provide the company with €450,000 additional funding as a loan.
This project positions Histocell as a pioneer and worldwide leader in the application of cell therapies in the treatment of lung diseases. In addition to the €3 million currently committed to this project, Histocell plans to undertake the later stages of the clinical development, for which will open soon a capital expansion round.
Genoma España is a state public-related sector Foundation, majority owned by the Ministry of Science and Innovation, which promotes the technology development and the knowledge and innovation transfer, especially in the biotechnology sector.